Cellectis announced that it entered into a new agreement for the cGMP manufacturing of UCART123 clinical batches, Cellectis' lead product candidate, with CELLforCURE, an LFB group company and the industrial facility for clinical and commercial production of innovative cell therapies in Europe. CELLforCURE will be in charge of implementing cGMP manufacturing processes designed and developed by Cellectis. Following the recent successful production of UCART19, pursuant to this second agreement CELLforCURE will be responsible for the manufacturing of cGMP clinical batches for UCART123, the lead engineered T-cell product candidate in Cellectis' wholly owned portfolio.

UCART123 targets CD123, an antigen expressed on the surface of cancer cells in malignancies, such as acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cells neoplasm (BPDCN). UCARTs (Universal Chimeric Antigen Receptor T-cells) are off-the-shelf" allogeneic product candidates. Their production can be industrialized and standardized with consistent pharmaceutical release criteria, over time and from batch to batch.

Peripheral Blood Monoculear Cells from healthy donors are transduced and genetically edited with Cellectis' TALEN technology to seek and destroy cancer cells. This approach could lead to a drug that would be cost-effective, made readily available - off the shelf" - to broad patient populations in hospitals without need for local CAR-T processing facilities and easily distributed across all geographies.